A study on a triple inhaler for COPD with hyperinflation
Part of Lungs & breathing clinical trials.
This study tests a triple-combination inhaler (budesonide, glycopyrronium, formoterol) against a placebo inhaler to see how it affects your heart and lungs if you have COPD and over-inflated lungs.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a current or former smoker with at least a 10 pack-year smoking history (e.g., smoked 1 pack/day for 10 years).
- You have a confirmed COPD diagnosis with moderate to severe airflow obstruction.
- Your lungs are over-inflated (more than 135% of the expected volume).
- You have had at least one COPD flare-up in the past year or are on ongoing maintenance treatment.
- You do not have asthma, a history of certain heart conditions, or a recent lung infection.
- If you are a woman who can become pregnant, you must use highly effective birth control.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new inhaler that combines three medicines (fluticasone, formoterol, and glycopyrronium) to see if it helps people with chronic obstructive pulmonary disease (COPD) breathe better and have fewer flare-ups. It may be an option if you have COPD and are looking for a convenient once- or twice-daily treatment.
This study looks at how well a triple-combination inhaler called Breztri/Trixeo works for people with moderate to severe COPD. If you have been prescribed this inhaler but haven't started it yet, and you are between 30 and 80 years old, you may be able to join.
This study tests a new inhaled powder medicine (TQC3927) against an existing combination inhaler for treating COPD, a lung disease that makes breathing difficult. The goal is to see if the new medicine works as well or better and is safe for people with COPD.
This trial tests if inhaled corticosteroids (ICS) work better for COPD patients with different eosinophil levels. You must already be taking two long-acting bronchodilators and have stopped smoking for at least 6 months.
This study looks at how often heart problems or stroke happen in people with COPD after they start a specific “triple therapy” inhaler. It may help doctors understand whether these inhalers change cardiovascular (heart) or cerebrovascular (stroke) risk.
This study tests a triple-combination inhaler (budesonide, glycopyrronium, and formoterol) to see if it can help protect the heart and lungs in people with COPD who also have heart problems or high risk for them.
Hear when a new Chronic Obstructive Pulmonary Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.